Testing a new gene therapy treatment for Friedreich's ataxia

This is an early-stage study testing a new gene therapy called SGT-212 in people with Friedreich's ataxia, a rare genetic condition that affects movement and coordination. Researchers want to learn whether this medication is safe and how well people tolerate it when given in two ways: directly into a specific part of the brain and through an IV infusion into the bloodstream. This treatment aims to help slow or improve symptoms of the disease.

Friedreich's ataxia is a serious genetic condition with no cure, and current treatment options are limited. This study exists to test whether this new gene therapy approach could offer a new way to treat the underlying cause of the disease and potentially help people maintain or improve their ability to move and function.